← Back to Search

CAR T-cell Therapy

OriCAR-017 for Multiple Myeloma

Phase 1
Recruiting
Research Sponsored by OriCell Therapeutics Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

Summary

This trial is the first study conducted by Oricell Therapeutics Inc. in the United States. It aims to assess the safety, how the body processes the drug, how the drug works in the

Who is the study for?
This trial is for adults aged 18-75 with relapsed/refractory multiple myeloma, who have tried at least three prior treatments and are refractory to the last one. They must meet specific criteria based on their type of myeloma protein levels and have a life expectancy over 12 weeks.
What is being tested?
The RIGEL Study is testing OriCAR-017, an anti-GPRC5D cell product by Oricell Therapeutics Inc., focusing on its safety, how it's processed in the body (PK/PD), and initial effectiveness in treating multiple myeloma patients.
What are the potential side effects?
While specific side effects for OriCAR-017 aren't listed here, similar therapies may cause immune reactions, infusion-related symptoms, fatigue, blood count changes, increased infection risk, and potential impact on organ function.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Dose-limiting toxicity (DLT)
Maximum tolerated dose (MTD) of OriCAR-017 US-P1
Secondary study objectives
Assessment of Clinical Benefit Rate (CBR)
Assessment of Disease Control Rate (DCR)
Assessment of Duration of Response (DOR) of treatment in patients with RR/MM
+6 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: OriCAR-017Experimental Treatment1 Intervention
Single OriCAR-017 infusion

Find a Location

Who is running the clinical trial?

OriCell Therapeutics Co., Ltd.Lead Sponsor
3 Previous Clinical Trials
203 Total Patients Enrolled
~54 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top